Dilated conjunctival vessels in a patient undergoing epoprostenol therapy.
A 44-year-old man with primary pulmonary hypertension was referred for a possible carotid-cavernous fistula. Since initiation of epoprostenol therapy 3 months prior to presentation, he noticed progressive redness in both eyes and a macular rash, primarily involving the face and abdomen. Examination revealed engorged superficial conjunctival vessels in both eyes. Magnetic resonance imaging and angiography of the brain and orbits revealed no evidence of an arteriovenous fistula. Epoprostenol, a vasodilator, was associated with dilated conjunctival vessels in this patient.
Foroozan
Rod
R
Chan-Kai
Brian
B
Marx
Douglas P
DP
D000328:Adult; D001808:Blood Vessels / Q000187:drug effects; D003228:Conjunctiva / Q000098:blood supply*; D011464:Epoprostenol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D008297:Male; D014664:Vasodilation; D014665:Vasodilator Agents / Q000009:adverse effects* / Q000627:therapeutic use
D014665:Vasodilator Agents; D011464:Epoprostenol